Molecular markers (c-erbB-2, p53) in breast cancer

被引:10
|
作者
Agrawal, Anil Kumar [1 ]
Jelen, Michal [2 ]
Rudnicki, Jerzy [1 ]
Grzebieniak, Zygmunt [1 ]
Zukrowski, Piotr [1 ]
Nienartowicz, Ewa [3 ]
机构
[1] Wroclaw Med Univ, Dept Gen & Oncol Surg 2, Wroclaw, Poland
[2] Wroclaw Med Univ, Dept Pathol, Wroclaw, Poland
[3] Wroclaw Med Univ, Dept Radiol, Wroclaw, Poland
关键词
breast cancer; molecular markers; p53; c-erbB-2;
D O I
10.2478/v10042-008-0059-7
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The aim of our study was to evaluate the correlation between clinical characteristics, histopatologic features and c-erbB-2 as well as p53 expression in cancer tissues. Breast cancer tissue was obtained from 184 female subjects with primary breast cancer. According to hormonal status patients were divided into two groups - 64 belonged to the premenopausal group and 120 to postmenopausal group. Each patient underwent mammectomy and axillary lymphadenectomy. c-erbB-2 protooncogene was detected in 54% cases, and was correlated with infiltrating type of cancer growth, as well as larger tumor size. The presence of p53 antioncogene was observed only in 33% of cases, mainly in infiltrating duct carcinomas. The incidence of c-erbB-2 and p53 positive cases was higher among subjects, whose ultrasound and mammography revealed malignancy. There was no correlation found between of c-erbB-2 expression and axillary lymph nodes involvement It seems probable, that c-erbB-2 and p53 status of cancer tissue may prove to be useful in assessment of the level of biological aggressiveness in breast carcinomas and hence can be used as a prognostic factor.
引用
收藏
页码:449 / 455
页数:7
相关论文
共 50 条
  • [1] p53 and c-erbB-2 as markers of resistance to adjuvant chemotherapy in breast cancer
    Tetu, B
    Brisson, J
    Plante, V
    Bernard, P
    MODERN PATHOLOGY, 1998, 11 (09) : 823 - 830
  • [2] Molecular biomarkers for breast cancer prognosis: Coexpression of c-erbB-2 and p53
    Beenken, SW
    Grizzle, WE
    Crowe, DR
    Conner, MG
    Weiss, HL
    Sellers, MT
    Krontiras, H
    Urist, MM
    Bland, KI
    ANNALS OF SURGERY, 2001, 233 (05) : 630 - 637
  • [3] IMMUNOHISTOCHEMICAL STUDY OF P53 AND C-ERBB-2 IN BREAST-CANCER
    CASTIGLIONI, T
    ELSNER, B
    CURUTCHET, HP
    MONTESINOS, M
    DEBONIS, D
    MEDICINA-BUENOS AIRES, 1995, 55 (05) : 415 - 420
  • [4] C-erbB-2 and p53 expression in breast cancer fine needle aspirates
    Tiniakos, DG
    Robinson, KB
    Greenwood, H
    Cullen, P
    Cook, AIM
    Horne, CHW
    Angus, B
    CYTOPATHOLOGY, 1996, 7 (03) : 178 - 186
  • [5] Immunohistochemical detection of c-erbB-2 and p53 in benign breast disease and breast cancer risk
    Rohan, TE
    Hartwick, W
    Miller, AB
    Kandel, RA
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (17): : 1262 - 1269
  • [6] p53 and neu (c-erbB-2) overexpression in relation to risk factors for breast cancer
    vanderKooy, K
    Rookus, MA
    Peterse, HL
    vanLeeuwen, FE
    HORMONAL CARCINOGENESIS II, 1996, : 378 - 382
  • [7] Angiogenesis, p53, and c-erbB-2 immunoreactivity and clinicopathological features in male breast cancer
    Shpitz, B
    Bomstein, Y
    Sternberg, A
    Klein, E
    Liverant, S
    Groisman, G
    Bernheim, J
    JOURNAL OF SURGICAL ONCOLOGY, 2000, 75 (04) : 252 - 257
  • [8] Molecular markers in breast cancer: Can we use c-erbB-2, p53, bcl-2 and bax gene expression as prognostic factors?
    Dimitrakakis, C
    Konstadoulakis, M
    Messaris, E
    Kymionis, G
    Karayannis, M
    Panoussopoulos, D
    Michalas, S
    Androulakis, G
    BREAST, 2002, 11 (04): : 279 - 285
  • [9] Value of c-erbB-2 and p53 oncoprotein co-overexpression in human breast cancer
    Barbati, A
    Cosmi, EV
    Sidoni, A
    Collini, P
    Porpora, MG
    Luthy, M
    Lauro, V
    Bucciarelli, E
    ANTICANCER RESEARCH, 1997, 17 (1A) : 401 - 405
  • [10] PROGNOSTIC-SIGNIFICANCE OF P53 AND C-ERBB-2 EXPRESSION IN OPERABLE BREAST-CANCER
    NOGUCHI, M
    KITAGAWA, H
    KINOSHITA, K
    MIYAZAKI, I
    SAITO, Y
    MIZUKAMI, Y
    INTERNATIONAL JOURNAL OF ONCOLOGY, 1993, 2 (04) : 587 - 591